SCHEMBL6399308

SCHEMBL6399308

CC(C)CCC(N(O)C=O)S(=O)(=O)Cc1ccc2sccc2c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.42
MMP13 P45452 1/20 0.42
CYP2A6 P11509 2/20 0.37
SIGMAR1 Q99720 2/20 0.35
OPRM1 P35372 1/20 0.34
OPRK1 P41145 1/20 0.34
PER2 O15055 1/20 0.34
CRY1 Q16526 1/20 0.34
CRY2 Q49AN0 1/20 0.34
CA12 O43570 4/20 0.33
CA2 P00918 4/20 0.33
CTNNB1 P35222 1/20 0.32
WNT3A P56704 1/20 0.32
TPSAB1 Q15661 1/20 0.31
PDE10A Q9Y233 1/20 0.31
BRD4 O60885 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6403070 0.90 MMP2 (0.38) MMP2MMP13CYP2A6SIGMAR1OPRM1
SCHEMBL6608273 0.88 CYP2A6 (0.40) MMP2MMP13CYP2A6SIGMAR1OPRM1
SCHEMBL6405762 0.88 SIGMAR1 (0.36) MMP2MMP13CYP2A6SIGMAR1OPRM1
SCHEMBL6399501 0.87 CYP2A6 (0.36) MMP2MMP13CYP2A6SIGMAR1OPRM1
SCHEMBL6399129 0.85 CTNNB1 (0.38) MMP2MMP13CYP2A6SIGMAR1PER2
SCHEMBL6398835 0.79 HDAC3 (0.33) MMP2MMP13SIGMAR1PER2CRY1
SCHEMBL6988385 0.79 CYP2A6 (0.36) MMP2MMP13CYP2A6SIGMAR1OPRM1
SCHEMBL6608264 0.79 CYP2A6 (0.40) MMP2MMP13CYP2A6SIGMAR1OPRM1
SCHEMBL6608267 0.79 CYP2A6 (0.40) MMP2MMP13CYP2A6SIGMAR1OPRM1
SCHEMBL6399305 0.77 CYP2A6 (0.36) MMP2MMP13CYP2A6SIGMAR1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides SMITHKLINE BEECHAM PLC 2005-12-29 US claimed
EP-1289980-B1 BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES SMITHKLINE BEECHAM PLC (GB) 2004-11-17 EP claimed
US-20040024066-A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides SMITHKLINE BEECHAM P.L.C. (GB) 2004-02-05 US claimed
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides SMITHKLINE BEECHAM PLC 2005-12-29 US disclosed
EP-1289980-B1 BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES SMITHKLINE BEECHAM PLC (GB) 2004-11-17 EP disclosed
US-20040024066-A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides SMITHKLINE BEECHAM P.L.C. (GB) 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides CD22, CD2, NEU3 MMP2 2931/4885MMP13 469/4885CYP2A6 486/4885
US-20040024066-A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides CD22, CD2, NEU3 MMP2 2846/4885MMP13 559/4885CYP2A6 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.